Fact based stock research
Mochida Pharmaceutical (TSE:4534)

JP3922800002

How to read the free ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

Mochida Pharmaceutical stock research in summary

mochida.co.jp

ANALYSIS: With an Obermatt Combined Rank of 92 (better than 92% compared with investment alternatives), Mochida Pharmaceutical (Pharmaceuticals, Japan) shares have much better financial characteristics than comparable stocks. Shares of Mochida Pharmaceutical are a good value (attractively priced) with a consolidated Value Rank of 90 (better than 90% of alternatives), are safely financed (Safety Rank of 100, which means low debt burdens), but show below-average growth (Growth Rank of 22). ...read more

RECOMMENDATION: A Combined Rank of 92, is a strong buy recommendation based on Mochida Pharmaceutical's financial characteristics. As the company Mochida Pharmaceutical's key financial metrics exhibit good value (Obermatt Value Rank of 90) but low growth (Obermatt Growth Rank of 22) while being safely financed (Obermatt Safety Rank of 100), it may be a safer investment because companies with low debt can better withstand times of crises. Yet the good value, better than 90% of comparable companies, may also indicate that the company's future is challenging. If you believe that low growth is temporary or just due to a specific current event, you may conclude that the good value of the stock provides an attractive investment opportunity and the downside is limited due to below-average financing risks. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more

Latest Obermatt Ranks


360° View^new
Sentiment Rank^new
Value Rank	90
Growth Rank	22
Safety Rank	100
Combined Rank	92

Country	Japan
Industry	Pharmaceuticals
Index
Size class	Small

24-Jul-2025. Stock data may be delayed. Log in or sign up to get the most recent research.

Further information

Multiple opinions. One number.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.

Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Review the performance ranks of the individual metrics that form each investment strategy.

Research History: Mochida Pharmaceutical

RESEARCH HISTORY	2022	2023	2024	2025
VALUE
VALUE	81	88	86	90
GROWTH
GROWTH	9	5	28	22
SAFETY
SAFETY	61	61	100	100
SENTIMENT
SENTIMENT	54	18	24	^new
360° VIEW
360° VIEW	41	45	75	^new

Most recent update of the stock research: 24-Jul-2025. Financial reporting date used for calculating ranks: 31-Mar-2025. Stock research history is based on the Obermatt Method. The higher the rank, the better Mochida Pharmaceutical is in the corresponding investment strategy.
Upgrade to a Premium Account to access the latest ranks.

Combined financial peformance in Detail

RESEARCH HISTORY	2022	2023	2024	2025
VALUE
VALUE	81	88	86	90
GROWTH
GROWTH	9	5	28	22
SAFETY
SAFETY	61	61	100	100
COMBINED
COMBINED	67	67	92	92

Last update of combined financial performance: 24-Jul-2025. Stock analysis on combined financial performance: The higher the rank of Mochida Pharmaceutical the better the performance.

Value Metrics in Detail

ANALYSIS: With an Obermatt Value Rank of 90 (better than 90% compared with alternatives) for 2025, Mochida Pharmaceutical shares are significantly less expensive than comparable stocks. The Value Rank is based on consolidating four value indicators that are all above average for Mochida Pharmaceutical. Price-to-Sales is 85 which means that the stock price compared with what market professionals expect for future sales is lower than for 85% of comparable companies, indicating a good value for Mochida Pharmaceutical's revenue size. The same is valid for expected Price-to-Profits, more favorable than for 54% of alternatives, and this is also true for the Price-to-Book capital ratio (also referred to as market-to-book ratio) with a Price-to-Capital Rank of 93. Compared with other companies in the same industry, dividend yields of Mochida Pharmaceutical are expected to be higher than for 72% of all competitors (a Dividend Yield rank of 72). ...read more

RECOMMENDATION: The overall picture with a consolidated Value Rank of 90, is a buy recommendation based on Mochida Pharmaceutical's stock price compared with the company's operational size and dividend yields. Since all value metrics are above the industry average, there is no objection to investing in Mochida Pharmaceutical based on its detailed value metrics. We recommend further analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks, including the 360° View, before making an investment decision. ...read more

VALUE METRICS	2022	2023	2024	2025
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	82	83	83	85
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	73	67	54	54
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	84	84	89	93
DIVIDEND YIELD
DIVIDEND YIELD	57	73	74	72
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	81	88	86	90

Last update of Value Rank: 24-Jul-2025. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Mochida Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

ANALYSIS: With an Obermatt Growth Rank of 22 (better than 22% compared with alternatives), Mochida Pharmaceutical shows one of the most restricted growth dynamics in its industry. There is little momentum in this company. The Growth Rank is based on consolidating four value indicators, with three out of four metrics below average for Mochida Pharmaceutical. While Profit Growth has a good rank of 64, as professionals currently expect the company to grow its profits more than 64% of its competitors, all other growth indicators are below market averages. Sales Growth has a rank of 34, which means that currently professionals expect the company to grow less than 66% of its competitors, while Capital Growth has a rank of 20 and Stock Returns have been below market median, with a rank of 40 (60% of alternative investments were better). ...read more

RECOMMENDATION: The overall picture with a consolidated Growth Rank of 22, is a sell recommendation for growth and momentum investors. While revenue growth and capital growth are good growth momentum indicators, profit is less reliable, because profits may increase due to cost-cutting measures which typically indicate negative growth momentum. "You can save a dollar only once" is the saying about such situations. Growth Investors should look at company priorities closely if they are interested in growth, because the increase in profits is not usually an indicator of growth, and stock prices have been below market, too. While momentum is a popular investment factor, the value aspect might be the more important one, in the longer term. We recommend analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks to arrive at a 360° View of the stock purchase case, especially since the growth performance is limited here. ...read more

GROWTH METRICS	2022	2023	2024	2025
REVENUE GROWTH
REVENUE GROWTH	14	9	12	34
PROFIT GROWTH
PROFIT GROWTH	33	27	34	64
CAPITAL GROWTH
CAPITAL GROWTH	18	27	33	20
STOCK RETURNS
STOCK RETURNS	47	43	68	40
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	9	5	28	22

Last update of Growth Rank: 24-Jul-2025. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Mochida Pharmaceutical.

Safety Metrics in Detail

ANALYSIS: With an Obermatt Safety Rank of 100 (better than 100% compared with alternatives) for 2025, the company Mochida Pharmaceutical has safe financing practices, which means that their overall debt burden is low. This doesn't mean that the business of Mochida Pharmaceutical is safe, it only means that the company is on the safer side regarding possible bankruptcy, assuming that public reporting is correct. The Safety Rank is based on consolidating three financing indicators, where all three are above average for Mochida Pharmaceutical. Leverage is at 95, meaning the company has a below-average debt-to-equity ratio. It has less debt than 95% of its competitors. Refinancing is at a rank of 94, meaning that the portion of the debt about to be refinanced is below average. It has less debt in the refinancing stage than 94% of its competitors. Finally, Liquidity is also good at a rank of 98, which means that the company generates more profit to service its debt than 98% of its competitors. ...read more

RECOMMENDATION: With a consolidated Safety Rank of 100 (better than 100% compared with alternatives), Mochida Pharmaceutical has a financing structure that is significantly safer than that of its competitors. These three positive financing indicators signal that the company is less likely to default on its debt obligations. However, it also means that its shareholder returns will be more modest if things go well. A low safety means fewer troubles in downtimes and less upside in good times. Investors may not have a debt issue with Mochida Pharmaceutical but they should also compare Obermatt’s Value, Growth, and Sentiment Ranks before making a decision. ...read more

SAFETY METRICS	2022	2023	2024	2025
LEVERAGE
LEVERAGE	100	100	97	95
REFINANCING
REFINANCING	93	93	91	94
LIQUIDITY
LIQUIDITY	82	82	100	98
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	61	61	100	100

Last update of Safety Rank: 24-Jul-2025. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Mochida Pharmaceutical and the more cash is available to service its debt.

Sentiment Metrics in Detail

SENTIMENT	2022	2023	2024	2025
ANALYST OPINIONS
ANALYST OPINIONS	n/a	20	20	^new
OPINIONS CHANGE
OPINIONS CHANGE	50	50	50	^new
PRO HOLDINGS
PRO HOLDINGS	67	26	38	^new
MARKET PULSE
MARKET PULSE	35	24	20	^new
CONSOLIDATED RANK: SENTIMENT
CONSOLIDATED RANK: SENTIMENT	54	18	24	^new

Last update of Sentiment Rank: 24-Jul-2025. Stock analysis on sentiment metrics: The higher the rank, the more positive the sentiment for Mochida Pharmaceutical.
Upgrade to a Premium Account to access the latest ranks.